Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy

Akira Goto, Yasutaka Sukawa, Hisayoshi Igarashi, Kei Onodera, Yuka Aoki, Kazuya Suzuki, Kazuhiko Yonezawa, Atsushi Yawata, Toshihisa Kobayashi, Hiroyuki Kaneto, Haruo Shimizu, Hideki Wakasugi, Yasutaka Matsunaga, Miki Itoh, Hiroyuki Okuda, Yoshiaki Arimura, Yasuhisa Shinomura

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: S-1, an oral fluoropyrimidine, is one of the standard chemotherapeutic agents for the treatment of metastatic gastric cancer (MGC). However, the most effective second-line regimen after failure of treatment with first-line agents such as S-1 is yet to be determined. The aim of this study was to investigate the various second-line chemotherapy regimens in MGC patients. Methods: We retrospectively studied patients with MGC who received second-line treatment after failure of the first-line S-1 or S-1/cisplatin treatment. The overall survival times with each second-line regimen were determined using the Kaplan-Meier method, and the effect on overall survival was analyzed using Cox regression analysis. Results: The median survival time for all patients was 14.2 months (95% confidence interval (CI): 12.88-15.43 months) with a 1-year survival rate of 60.4%. Kaplan-Meier analysis revealed that the second-line regimens containing irinotecan significantly improved the median survival time as compared to regimens without irinotecan (median survival time: 16.5 and 13.8 months, respectively). Cox regression analysis showed that irinotecan-containing regimens were associated with improved overall survival (hazard ratio: 0.165; 95% CI: 0.041-0.665). Conclusion: The use of irinotecan-containing regimens as second-line chemotherapy after failure of first-line S-1 therapy may be beneficial for MGC patients.

Original languageEnglish
Pages (from-to)1461-1466
Number of pages6
JournalJapanese Journal of Cancer and Chemotherapy
Volume38
Issue number9
Publication statusPublished - 2011 Sep
Externally publishedYes

Fingerprint

irinotecan
Stomach Neoplasms
Survival
Treatment Failure
Therapeutics
Regression Analysis
Confidence Intervals
Drug Therapy
Kaplan-Meier Estimate
Cisplatin
Survival Rate

Keywords

  • Gastric cancer
  • Irinotecan
  • S-1
  • Second-line chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy. / Goto, Akira; Sukawa, Yasutaka; Igarashi, Hisayoshi; Onodera, Kei; Aoki, Yuka; Suzuki, Kazuya; Yonezawa, Kazuhiko; Yawata, Atsushi; Kobayashi, Toshihisa; Kaneto, Hiroyuki; Shimizu, Haruo; Wakasugi, Hideki; Matsunaga, Yasutaka; Itoh, Miki; Okuda, Hiroyuki; Arimura, Yoshiaki; Shinomura, Yasuhisa.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 38, No. 9, 09.2011, p. 1461-1466.

Research output: Contribution to journalArticle

Goto, A, Sukawa, Y, Igarashi, H, Onodera, K, Aoki, Y, Suzuki, K, Yonezawa, K, Yawata, A, Kobayashi, T, Kaneto, H, Shimizu, H, Wakasugi, H, Matsunaga, Y, Itoh, M, Okuda, H, Arimura, Y & Shinomura, Y 2011, 'Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy', Japanese Journal of Cancer and Chemotherapy, vol. 38, no. 9, pp. 1461-1466.
Goto, Akira ; Sukawa, Yasutaka ; Igarashi, Hisayoshi ; Onodera, Kei ; Aoki, Yuka ; Suzuki, Kazuya ; Yonezawa, Kazuhiko ; Yawata, Atsushi ; Kobayashi, Toshihisa ; Kaneto, Hiroyuki ; Shimizu, Haruo ; Wakasugi, Hideki ; Matsunaga, Yasutaka ; Itoh, Miki ; Okuda, Hiroyuki ; Arimura, Yoshiaki ; Shinomura, Yasuhisa. / Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy. In: Japanese Journal of Cancer and Chemotherapy. 2011 ; Vol. 38, No. 9. pp. 1461-1466.
@article{4929c72a66a54ecb87e5787452c78e9c,
title = "Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy",
abstract = "Background: S-1, an oral fluoropyrimidine, is one of the standard chemotherapeutic agents for the treatment of metastatic gastric cancer (MGC). However, the most effective second-line regimen after failure of treatment with first-line agents such as S-1 is yet to be determined. The aim of this study was to investigate the various second-line chemotherapy regimens in MGC patients. Methods: We retrospectively studied patients with MGC who received second-line treatment after failure of the first-line S-1 or S-1/cisplatin treatment. The overall survival times with each second-line regimen were determined using the Kaplan-Meier method, and the effect on overall survival was analyzed using Cox regression analysis. Results: The median survival time for all patients was 14.2 months (95{\%} confidence interval (CI): 12.88-15.43 months) with a 1-year survival rate of 60.4{\%}. Kaplan-Meier analysis revealed that the second-line regimens containing irinotecan significantly improved the median survival time as compared to regimens without irinotecan (median survival time: 16.5 and 13.8 months, respectively). Cox regression analysis showed that irinotecan-containing regimens were associated with improved overall survival (hazard ratio: 0.165; 95{\%} CI: 0.041-0.665). Conclusion: The use of irinotecan-containing regimens as second-line chemotherapy after failure of first-line S-1 therapy may be beneficial for MGC patients.",
keywords = "Gastric cancer, Irinotecan, S-1, Second-line chemotherapy",
author = "Akira Goto and Yasutaka Sukawa and Hisayoshi Igarashi and Kei Onodera and Yuka Aoki and Kazuya Suzuki and Kazuhiko Yonezawa and Atsushi Yawata and Toshihisa Kobayashi and Hiroyuki Kaneto and Haruo Shimizu and Hideki Wakasugi and Yasutaka Matsunaga and Miki Itoh and Hiroyuki Okuda and Yoshiaki Arimura and Yasuhisa Shinomura",
year = "2011",
month = "9",
language = "English",
volume = "38",
pages = "1461--1466",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "9",

}

TY - JOUR

T1 - Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy

AU - Goto, Akira

AU - Sukawa, Yasutaka

AU - Igarashi, Hisayoshi

AU - Onodera, Kei

AU - Aoki, Yuka

AU - Suzuki, Kazuya

AU - Yonezawa, Kazuhiko

AU - Yawata, Atsushi

AU - Kobayashi, Toshihisa

AU - Kaneto, Hiroyuki

AU - Shimizu, Haruo

AU - Wakasugi, Hideki

AU - Matsunaga, Yasutaka

AU - Itoh, Miki

AU - Okuda, Hiroyuki

AU - Arimura, Yoshiaki

AU - Shinomura, Yasuhisa

PY - 2011/9

Y1 - 2011/9

N2 - Background: S-1, an oral fluoropyrimidine, is one of the standard chemotherapeutic agents for the treatment of metastatic gastric cancer (MGC). However, the most effective second-line regimen after failure of treatment with first-line agents such as S-1 is yet to be determined. The aim of this study was to investigate the various second-line chemotherapy regimens in MGC patients. Methods: We retrospectively studied patients with MGC who received second-line treatment after failure of the first-line S-1 or S-1/cisplatin treatment. The overall survival times with each second-line regimen were determined using the Kaplan-Meier method, and the effect on overall survival was analyzed using Cox regression analysis. Results: The median survival time for all patients was 14.2 months (95% confidence interval (CI): 12.88-15.43 months) with a 1-year survival rate of 60.4%. Kaplan-Meier analysis revealed that the second-line regimens containing irinotecan significantly improved the median survival time as compared to regimens without irinotecan (median survival time: 16.5 and 13.8 months, respectively). Cox regression analysis showed that irinotecan-containing regimens were associated with improved overall survival (hazard ratio: 0.165; 95% CI: 0.041-0.665). Conclusion: The use of irinotecan-containing regimens as second-line chemotherapy after failure of first-line S-1 therapy may be beneficial for MGC patients.

AB - Background: S-1, an oral fluoropyrimidine, is one of the standard chemotherapeutic agents for the treatment of metastatic gastric cancer (MGC). However, the most effective second-line regimen after failure of treatment with first-line agents such as S-1 is yet to be determined. The aim of this study was to investigate the various second-line chemotherapy regimens in MGC patients. Methods: We retrospectively studied patients with MGC who received second-line treatment after failure of the first-line S-1 or S-1/cisplatin treatment. The overall survival times with each second-line regimen were determined using the Kaplan-Meier method, and the effect on overall survival was analyzed using Cox regression analysis. Results: The median survival time for all patients was 14.2 months (95% confidence interval (CI): 12.88-15.43 months) with a 1-year survival rate of 60.4%. Kaplan-Meier analysis revealed that the second-line regimens containing irinotecan significantly improved the median survival time as compared to regimens without irinotecan (median survival time: 16.5 and 13.8 months, respectively). Cox regression analysis showed that irinotecan-containing regimens were associated with improved overall survival (hazard ratio: 0.165; 95% CI: 0.041-0.665). Conclusion: The use of irinotecan-containing regimens as second-line chemotherapy after failure of first-line S-1 therapy may be beneficial for MGC patients.

KW - Gastric cancer

KW - Irinotecan

KW - S-1

KW - Second-line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=81855169506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855169506&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:81855169506

VL - 38

SP - 1461

EP - 1466

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 9

ER -